Coral Laboratories Share Price Today | Stock Price & Coral Laboratories Share Screener
As of October 5, 2026, the live Coral Laboratories share price (BSE: CORALAB) is ₹561.90, up 2.42% from the previous close, with shares trading between ₹561.00 and ₹584.50 in today's trading session, and a 52-week range of ₹362.05–₹665.15. Check CORALAB price range for the annual price range and momentum. Use the Coral Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Coral Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹107 and net income of ₹19, with EBITDA of ₹29, an operating margin of 19.0% and a profit margin of 17.8%.
Coral Laboratories Share Price Chart
Track the current stock price of Coral Laboratories with an interactive chart. Analyse CORALAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Coral Laboratories stock quote in one place.
The quote of ₹561.90 sits between the 52-week low of ₹362.05 and the 52-week high of ₹665.15, and the latest session moved 2.42% from the previous close.
Coral Laboratories Company Profile - Fundamental Screener
Screen Coral Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CORALAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE683E01017.
Company Details
Classification
Identifiers and Leadership
Coral Laboratories Balance Sheet Screener
Screen CORALAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹241, up from ₹230 in 2025.
Latest statistics put total assets at ₹241 and shareholder funds at ₹209, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 241 | 230 | 206 | 174 | 190 | 168 | 144 | 136 | 140 | 131 |
| Current Assets | 177 | 177 | 154 | 124 | 131 | 129 | 96 | 84 | 72 | 74 |
| Fixed Assets | 44 | 23 | 24 | 25 | 24 | 21 | 23 | 23 | 22 | 18 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 4 | 3 | 3 | 8 | 8 | 3 | 4 | 4 | 4 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 209 | 201 | 178 | 155 | 156 | 137 | 116 | 114 | 116 | 109 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 206 | 198 | 174 | 151 | 153 | 133 | 112 | 110 | 113 | 106 |
Coral Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Coral Laboratories income statement and profit fundamentals. Analyze CORALAB quarterly results. Coral Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹107 and net profit was ₹19, equal to earnings per unit of ₹53.80, at an operating margin of 19%.
In that period expenses were ₹78, interest cost ₹0 and tax ₹6. The next period listed, 2026-March, shows revenue of ₹96 and net profit of ₹16.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 107 | 96 | 124 | 90 | 85 | 80 | 100 | 77 | 96 | 97 | 99 | 80 | 62 |
| Expenses | 78 | 71 | 89 | 67 | 74 | 67 | 81 | 65 | 79 | 77 | 72 | 61 | 47 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 29 | 25 | 35 | 23 | 11 | 13 | 20 | 11 | 17 | 20 | 27 | 19 | 15 |
| Operating Profit % | 19.00% | 18.00% | 23.00% | 19.00% | 5.00% | 11.00% | 16.00% | 8.00% | 13.00% | 16.00% | 24.00% | 21.00% | 21.00% |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 26 | 23 | 33 | 21 | 8 | 12 | 18 | 9 | 16 | 18 | 25 | 17 | 12 |
| Tax | 6 | 7 | 8 | 5 | 2 | 3 | 4 | 2 | 5 | 6 | 8 | 5 | 3 |
| Net Profit | 19 | 16 | 24 | 16 | 6 | 9 | 14 | 7 | 10 | 12 | 16 | 12 | 10 |
| EPS | 53.80 | 45.85 | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 | 19.96 | 28.60 | 34.84 | 45.61 | 34.70 | 26.79 |
Coral Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen CORALAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹16, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹18 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 16 | -1 | -6 | 13 | 6 | 1 | -4 | -1 | 14 | 11 |
| Investing Activities | -18 | 0 | 1 | -3 | -6 | 0 | -2 | 3 | -13 | -10 |
Financing and Net Cash | ||||||||||
| Financing Activities | 0 | 3 | 0 | -6 | 0 | 0 | 4 | -1 | -3 | 1 |
| Net Cash Flow | -2 | 1 | -4 | 4 | 0 | 1 | -2 | 1 | -2 | 2 |
Coral Laboratories Shareholding Pattern Screener
See Coral Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Coral Laboratories promoter holding and ownership changes for CORALAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 71.51%, foreign institutions 0.00%, domestic institutions 0.00% and the public 19.93%, spread across 4,084 shareholders.
The shareholder count was 4,084 in 2026-Mar, compared with 3,873 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.14% | 0.23% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 19.93% | 19.93% | 20.91% | 20.76% | 20.80% | 20.52% | 20.82% | 20.33% |
| Other Holding | 8.56% | 8.56% | 7.58% | 7.72% | 7.69% | 7.97% | 7.52% | 7.93% |
| Shareholder Count | 4,084 | 3,873 | 4,105 | 4,213 | 4,286 | 4,208 | 4,098 | 3,831 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Coral Laboratories. Coral Laboratories dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹2.00 per unit for 2026-March, a yield of 0.36%, compared with ₹1.50 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹2.00, ₹1.50 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹2.00 | 0.36% |
| 2025-March | ₹1.50 | 0.40% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹2.00 | 2.04% |
| 2018-March | ₹2.00 | 0.63% |
| 2017-March | ₹5.00 | 0.84% |
Coral Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Coral Laboratories stock. Check CORALAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Coral Laboratories Market Events Screener - Corporate Actions
Get Coral Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Coral Laboratories stock events that may affect CORALAB share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 29, 2026, with a record date of September 29, 2026.
It is followed by Dividend dated September 22, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-29 | 2026-09-29 | Annual General Meeting | NA | -3.91% |
| 2026-09-22 | 2026-09-22 | Dividend | ₹ 2.00 /share | 21.73% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | -1.14% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 3.37% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 9.27% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 0.41% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -5.28% |
| 2025-09-19 | 2025-09-19 | Dividend | ₹ 1.50 /share | -28.37% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -3.21% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 4.18% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -8.05% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -2.11% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | 21.88% |
| 2024-09-20 | 2024-09-21 | Dividend | ₹ 2.00 /share | 23.19% |
Coral Laboratories Competitors Screener - Peer Stocks Comparison
Screen CORALAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Coral Laboratories Company Announcements - News & Reports Screener
Screen CORALAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 1, 2026 and September 27, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-27 | Board Meeting Outcome for Considered And Approved Cost Audit Report In CRA-3 For The Financial Year 2025-26 | - |
| 2026-09-21 | Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On September 25 2026 | - |
| 2026-09-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Reg. 34 (1) Annual Report. | - |
| 2026-09-04 | Notice Of 44Th AGM Scheduled To Be Held On September 29 2026 | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Notice Of Book Closure | - |
| 2026-08-14 | Intimation For Holding 44Th AGM | - |
| 2026-08-14 | Financial Results For The Quarter Ended On June 30 2026 | - |
| 2026-08-14 | Notice Of Book Closure And Record Date | - |
| 2026-08-14 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-05 | Board Meeting Intimation for Intimation Of Board Meeting | - |
| 2026-07-23 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-07-23 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-25 | Reply To Clarification | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹561.90, within a 52-week range of ₹362.05 to ₹665.15. The P/E ratio is 10.56 and the P/B ratio is 0.97, with earnings per unit of ₹45.85. Market capitalisation stands at ₹203.14 Cr and the dividend yield is 0.35%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.